Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics?
De Hert, Marc; Van Eyck, Dominique; Hanssens, Lindaet al.
[en] Objective. - A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies. Method. - A large scale prospective study on metabolic risks of antipsychotic medication is currently ongoing. At baseline, patients get a full laboratory screening, ECG and an oral glucose tolerance test (OGTT). Baseline data on 100 non-diabetic patients at study inclusion and stable on medication for at least 6 months are presented. Results. - Glucose abnormalities are found in 22% of patients at baseline, A monitoring protocol based only on fasting glucose would not have detected 63.6% of these patients with classifiable glucose abnormalities in our sample. Fasting insulin and measures for insulin resistance have a high predictive value for abnormalities late in the OGTT. Conclusion. - Already at baseline, metabolic problems are frequently present in patients with schizophrenia treated with antipsychotics. Adding assessment of fasting insulin in a monitoring protocol improves detection of glucose abnormalities late in an OGTT. (c) 2005 Elsevier SAS. All rights reserved.
Disciplines :
Endocrinology, metabolism & nutrition Psychiatry
Author, co-author :
De Hert, Marc
Van Eyck, Dominique
Hanssens, Linda
Peuskens, Hendrik
Thys, Erik
Wampers, Martien
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Peuskens, Jozef
Language :
English
Title :
Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics?
Publication date :
June 2006
Journal title :
European Psychiatry
ISSN :
0924-9338
eISSN :
1778-3585
Publisher :
Elsevier France-Editions Scientifiques Medicales Elsevier, Paris, France
American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 2 (2004) 596-601
Caro J.J., Ward A., Levinton C., and Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J. Clin. Psychiatry 63 12 (2002) 1135-1139
Citrome L.L., and Jaffe A.B. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann. Pharmacother. 37 (2003) 1849-1857
De Hert M., Hanssens L., de Patoul A., and Peuskens J. Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Schiz. Res. 67 (2004) (Abstracts Winter Workshop on Schizophrenia)
De Nayer A., DeHert M., Scheen A., et al. Belgian consensus on metabolic problems associated with second generation antipsychotics. Int. J. Psychiatry Clin. Pract. 9 (2005) 130-137
Ebenbilcher C., Laimer M., Eder U., Mangwerth B., Weiss E., Hofer A., et al. Olanzapine induced insulin resistance: results from a prospective study. J. Clin. Psychiatry 64 12 (2003) 1436-1439
Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J. Clin. Psychiatry 57 (2002) 12-15
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26, Suppl 1 (2003) S5-S20
Expert Group. Schizophrenia and diabetes 2003. Expert consensus meeting, Dublin 3-4 October 2003: consensus summary. Brit. J. Psy. 184 (2004) S112-S114
Expert Panel on Detection. Evaluation and treatment of blood cholesterol in adults. Extensive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 285 (2001) 2486-2497
Gianfrancesco F., White R., Wang R.H., and Nasrallah H.A. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J. Clin. Psychopharmacol. 23 4 (2003) 328-335
Hedenmalm K., Hagg S., Stahl M., Mortimer O., and Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf. 25 15 (2002) 1107-1116
Henderson D.C. Atypical antipsychotic-induced diabetes mellitus, how strong is the evidence. CNS Drugs 16 (2002) 77-89
Howes O.D., Bhatnagar A., Gaugran F.P., Amiel S.A., Murray R.M., and Pilowsky L.S. A prospective study of impairement in glucose control caused by clozapine without changes in insulin resistance. Am. J. Psychiatry 161 (2004) 361-363
Lean M.E., and Pajonk F.G. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 26 5 (2003) 1597-1605
Lorenzo C., Okoloise M., Williams K., Stern M.P., and Haffner S.M. The metabolic syndrome as predictor of Type-2 diabetes. Diabetes Care 26 (2003) 3153-3159
Lindenmayer J.P., Czobor P., Volavka J., Citrome L.L., Sheitman B., McEvoy J.P., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical and atypical antipsychotics. Am. J. Psychiatry 160 (2003) 290-296
Melkersson K., and Dahl M.-L. Adverse metabolic effects associated with atypical antipsychotics. Drugs (2004) 701-723
Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., et al. Abnormalities in glucose regulation during antipsychotic treatment. Arch. Gen. Psychiatry 59 (2002) 337-345
Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., and Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 159 4 (2002) 561-566
Stern M.P., Williams K., and Haffner S.M. Identification of persons at high risk for Type-2 diabetes: do we need the oral glucose tolerance test. Ann. Intern. Med. 136 (2002) 575-581
Wampers M., De Hert M., Van Eyck D., and Peuskens J. Somatic medication in hospitalised schizophrenic patients in Belgium. Schiz. Res. 67 (2004) (Abstracts Winter Workshop on Schizophrenia)